The future of warfarin pharmacogenetics in under-represented minority groups

Pharmacogenetics of Warfarin

วารสารโลหติวทิยาและเวชศาสตร บรกิารโลหติ ป ที ่ 16 ฉบบัที ่ 3 กรกฎาคม-กนัยายน 2549 Warfarin is the mainstay of anticoagulation therapy. It is used for the prevention and treatment of venous thromboembolism, myocardial infarction, and strokes.1 Its clinical use, however, is complicated by the fact that it has a narrow therapeutic index with associated adverse effects that are potentially serious,...

Cardiac rehabilitation in the UK: uptake among under-represented groups.

T he National Service Framework for coronary heart disease (CHD) states that cardiac rehabilitation should be provided for all patients who may benefit, and that priority should be given in the first instance to those who have survived a myocardial infarction (MI) or undergone revascularisation. This was recently endorsed by the fifth report on the provision of services for patients with heart ...

Warfarin pharmacogenetics meets clinical use.

ence is sufficient to disrupt the nucleolar structure.9 Similarly, the anticancer peptide CIGB-300 leads to nucleolar disassembly and apoptosis, most likely through its capability to bind NPM1.10 Because AML cells carrying the NPM1 mutation are depleted of wild-type NPM1 protein in their nucleolar pool (because of haploinsufficiency and cytoplasmic dislocation through formation of heterodimers ...

Warfarin: a case history in pharmacogenetics.

Both hereditary and environmental factors contribute to inter-individual variability in drug response. The considerable interest in the role of genes has to be balanced with the contribution of external influences. Warfarin provides a useful case study of the need to integrate both genetic and non-genetic information when selecting the right dose for a patient. This article discusses the latest...

A letter to the editor: under-represented minority faculty in academic medical centers.